CCL22 and primary cutaneous T-cell non-Hodgkin lymphoma: Since bexarotene reduces both the expression of CCR4 in CTCL cells and CCL22 production from TAMs to inhibit the migration of CCR4‐expressing cells,13, 14 investigating the subset of CCR4‐expressing cells in the lesional skin of CTCL might help predict the efficacy of bexarotene.